How I safely transfuse patients with sickle-cell disease and manage delayed hemolytic transfusion reactions

Blood

Volumn 131, Issue 25, 2018, Pages 2773-2781

  Pirenne, France ^a,b   Yazdanbakhsh, Karina ^c  

^a Laboratoire d Excellence CORAIL   (France)

^b UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^c NEW YORK BLOOD CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BILIRUBIN; ECULIZUMAB; ERYTHROPOIETIN; HAPTOGLOBIN; HEMOGLOBIN; HEMOPEXIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; LACTATE DEHYDROGENASE; RHESUS E ANTIBODY; RITUXIMAB;

ADULT; ALLOIMMUNIZATION; ANTICOAGULANT THERAPY; ARTICLE; BLOOD GROUP; BLOOD GROUP TYPING; BLOOD TRANSFUSION; BLOOD TRANSFUSION REACTION; CASE REPORT; CLINICAL ARTICLE; CONTROL STRATEGY; DELAYED HEMOLYTIC TRANSFUSION REACTION; ERYTHROCYTE; ERYTHROCYTE TRANSFUSION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOGLOBINURIA; HEMOLYSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MULTIPLE CYCLE TREATMENT; PAIN; PATIENT SAFETY; PLASMA EXCHANGE; PRIORITY JOURNAL; RISK FACTOR; SICKLE CELL ANEMIA; THROMBOSIS; THROMBOSIS PREVENTION; DISEASE MANAGEMENT; PROCEDURES;

ADULT; ANEMIA, SICKLE CELL; DISEASE MANAGEMENT; ERYTHROCYTE TRANSFUSION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; TRANSFUSION REACTION;

EID: 85048993437     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2018-02-785964     Document Type: Article

References (66)

1. Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med. 1998;339(1):5-11.
2. Cohen AR, Martin MB, Silber JH, Kim HC, Ohene-Frempong K, Schwartz E. A modified transfusion program for prevention of stroke in sickle cell disease. Blood. 1992;79(7): 1657-1661.
3. Oteng-Ntim E, Meeks D, Seed PT, et al. Adverse maternal and perinatal outcomes in pregnant women with sickle cell disease: systematic review and meta-analysis. Blood. 2015;125(21):3316-3325.
4. Petz LD, Calhoun L, Shulman IA, Johnson C, Herron RM. The sickle cell hemolytic transfusion reaction syndrome. Transfusion. 1997; 37(4):382-392.
5. Habibi A, Mekontso-Dessap A, Guillaud C, et al. Delayed hemolytic transfusion reaction in adult sickle-cell disease: presentations, outcomes, and treatments of 99 referral center episodes. Am J Hematol. 2016;91(10): 989-994.
6. Talano JA, Hillery CA, Gottschall JL, Baylerian DM, Scott JP. Delayed hemolytic transfusion reaction/hyperhemolysis syndrome in children with sickle cell disease. Pediatrics. 2003; 111(6):e661-e665.
7. King KE, Shirey RS, Lankiewicz MW, Young-Ramsaran J, Ness PM. Delayed hemolytic transfusion reactions in sickle cell disease: simultaneous destruction of recipients’ red cells. Transfusion. 1997;37(4):376-381.
8. Win N, New H, Lee E, de la Fuente J. Hyperhemolysis syndrome in sickle cell disease: case report (recurrent episode) and literature review. Transfusion. 2008;48(6): 1231-1238.
9. Vidler JB, Gardner K, Amenyah K, Mijovic A, Thein SL. Delayed haemolytic transfusion reaction in adults with sickle cell disease: a 5-year experience. Br J Haematol. 2015; 169(5):746-753.
10. Adisa OA, Hu Y, Ghosh S, Aryee D, Osunkwo I, Ofori-Acquah SF. Association between plasma free haem and incidence of vaso-occlusive episodes and acute chest syndrome in children with sickle cell disease. Br J Haematol. 2013;162(5):702-705.
11. hi patrolling monocytes protect against vaso-occlusion in sickle cell disease. Blood. 2018;131(14): 1600-1610.
12. Ngo S, Bartolucci P, Lobo D, et al. Causes of death in sickle cell disease adult patients: old and new trends [abstract]. Blood. 2014; 124(21). Abstract 2715.
13. Rosse WF, Gallagher D, Kinney TR, et al; The Cooperative Study of Sickle Cell Disease. Transfusion and alloimmunization in sickle cell disease. Blood. 1990;76(7):1431-1437.
14. Vichinsky EP, Earles A, Johnson RA, Hoag MS, Williams A, Lubin B. Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood. N Engl J Med. 1990;322(23): 1617-1621.
15. Aygun B, Padmanabhan S, Paley C, Chandrasekaran V. Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions. Transfusion. 2002;42(1):37-43.
16. Natukunda B, Schonewille H, Ndugwa C, Brand A. Red blood cell alloimmunization in sickle cell disease patients in Uganda. Transfusion. 2010;50(1):20-25.
17. Godfrey GJ, Lockwood W, Kong M, Bertolone S, Raj A. Antibody development in pediatric sickle cell patients undergoing eryth-rocytapheresis. Pediatr Blood Cancer. 2010; 55(6):1134-1137.
18. Chou ST, Liem RI, Thompson AA. Challenges of alloimmunization in patients with haemo-globinopathies. Br J Haematol. 2012;159(4): 394-404.
19. Sins JWR, Biemond BJ, van den Bersselaar SM, et al. Early occurrence of red blood cell alloimmunization in patients with sickle cell disease. Am J Hematol. 2016;91(8):763-769.
20. Hendrickson JE, Hod EA, Perry JR, et al. Alloimmunization to transfused HOD red blood cells is not increased in mice with sickle cell disease. Transfusion. 2012;52(2):231-240.
21. Fasano RM, Booth GS, Miles M, et al. Red blood cell alloimmunization is influenced by recipient inflammatory state at time of transfusion in patients with sickle cell disease. Br J Haematol. 2015;168(2):291-300.
22. Tatari-Calderone Z, Minniti CP, Kratovil T, et al. rs660 polymorphism in Ro52 (SSA1; TRIM21) is a marker for age-dependent tolerance induction and efficiency of alloimmunization in sickle cell disease. Mol Immunol. 2009;47(1):64-70.
23. Schonewille H, Doxiadis II, Levering WH, Roelen DL, Claas FH, Brand A. HLA-DRB1 associations in individuals with single and multiple clinically relevant red blood cell antibodies. Transfusion. 2014;54(8):1971-1980.
24. Tatari-Calderone Z, Tamouza R, Le Bouder GP, et al The association of CD81 polymorphisms with alloimmunization in sickle cell disease. Clin Dev Immunol. 2013;2013: 937846.
25. Oliveira VB, Dezan MR, Gomes FCA, et al. -318C/T polymorphism of the CTLA-4 gene is an independent risk factor for RBC alloimmunization among sickle cell disease patients. Int J Immunogenet. 2017;44(5):219-224.
26. Meinderts SM, Sins JWR, Fijnvandraat K, et al. Nonclassical FCGR2C haplotype is associated with protection from red blood cell alloimmunization in sickle cell disease. Blood. 2017; 130(19):2121-2130.
27. Zhong H, Bao W, Friedman D, Yazdanbakhsh K. Hemin controls T cell polarization in sickle cell alloimmunization. J Immunol. 2014; 193(1):102-110.
28. Godefroy E, Liu Y, Shi P, et al. Altered heme-mediated modulation of dendritic cell function in sickle cell alloimmunization. Haematologica. 2016;101(9):1028-1038.
29. Vingert B, Tamagne M, Habibi A, et al. Phenotypic differences of CD4(1) T cells in response to red blood cell immunization in transfused sickle cell disease patients. Eur J Immunol. 2015;45(6):1868-1879.
30. Godefroy E, Zhong H, Pham P, Friedman D, Yazdanbakhsh K. TIGIT-positive circulating follicular helper T cells display robust B-cell help functions: potential role in sickle cell alloimmunization. Haematologica. 2015; 100(11):1415-1425.
31. Bao W, Zhong H, Li X, et al. Immune regulation in chronically transfused allo-antibody responder and nonresponder patients with sickle cell disease and b-thalassemia major. Am J Hematol. 2011;86(12):1001-1006.
32. Bao W, Zhong H, Manwani D, et al. Regulatory B-cell compartment in transfused alloimmunized and non-alloimmunized patients with sickle cell disease. Am J Hematol. 2013;88(9): 736-740.
33. Vingert B, Tamagne M, Desmarets M, et al. Partial dysfunction of Treg activation in sickle cell disease [published correction appears in Am J Hematol. 2015;90(1):84]. Am J Hematol. 2014;89(3):261-266.
34. Vichinsky EP, Luban NL, Wright E, et al; Stroke Prevention Trail in Sickle Cell Anemia. Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial. Transfusion. 2001;41(9):1086-1092.
35. Osby M, Shulman IA. Phenotype matching of donor red blood cell units for nonalloimmunized sickle cell disease patients: a survey of 1182 North American laboratories. Arch Pathol Lab Med. 2005;129(2):190-193.
36. LaSalle-Williams M, Nuss R, Le T, et al. Extended red blood cell antigen matching for transfusions in sickle cell disease: a review of a 14-year experience from a single center (CME). Transfusion. 2011;51(8):1732-1739.
37. Chou ST, Jackson T, Vege S, Smith-Whitley K, Friedman DF, Westhoff CM. High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors. Blood. 2013;122(6): 1062-1071.
38. Silvy M, Tournamille C, Babinet J, et al. Red blood cell immunization in sickle cell disease: evidence of a large responder group and a low rate of anti-Rh linked to partial Rh phenotype. Haematologica. 2014;99(7):e115-e117.
39. Noizat-Pirenne F, Lee K, Pennec PY, et al. Rare RHCE phenotypes in black individuals of Afro-Caribbean origin: identification and transfusion safety. Blood. 2002;100(12):4223-4231.
40. Yazdanbakhsh K, Ware RE, Noizat-Pirenne F. Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management. Blood. 2012;120(3): 528-537.
41. Wilkinson K, Harris S, Gaur P, et al. Molecular blood typing augments serologic testing and allows for enhanced matching of red blood cells for transfusion in patients with sickle cell disease. Transfusion. 2012;52(2):381-388.
42. Floch A, Gien D, Tournamille C, et al. High immunogenicity of red blood cell antigens restricted to the population of African descent in a cohort of sickle cell disease patients [published online ahead of print 29 April 2018]. Transfusion. doi:10.1111/trf.14633.
43. Noizat-Pirenne F, Bachir D, Chadebech P, et al. Rituximab for prevention of delayed hemolytic transfusion reaction in sickle cell disease. Haematologica. 2007;92(12): e132-e135.
44. Larson PJ, Lukas MB, Friedman DF, Manno CS. Delayed hemolytic transfusion reaction due to anti-Go(a), an antibody against the low-prevalence Gonzales antigen. Am J Hematol. 1996;53(4):248-250.
45. Noizat-Pirenne F, Habibi A, Mekontso-Dessap A, et al. The use of rituximab to prevent severe delayed haemolytic transfusion reaction in immunized patients with sickle cell disease. Vox Sang. 2015;108(3):262-267.
46. Bachmeyer C, Maury J, Parrot A, et al. Rituximab as an effective treatment of hyperhemolysis syndrome in sickle cell anemia. Am J Hematol. 2010;85(1):91-92.
47. Nickel RS, Hendrickson JE, Fasano RM, et al. Impact of red blood cell alloimmunization on sickle cell disease mortality: a case series. Transfusion. 2016;56(1):107-114.
48. Narbey D, Habibi A, Chadebech P, et al. Incidence and predictive score for delayed hemolytic transfusion reaction in adult patients with sickle cell disease. Am J Hematol. 2017;92(12):1340-1348.
49. Tormey CA, Stack G. The persistence and evanescence of blood group alloantibodies in men. Transfusion. 2009;49(3):505-512.
50. Frimat M, Tabarin F, Dimitrov JD, et al. Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome. Blood. 2013;122(2):282-292.
51. Chadebech P, Habibi A, Nzouakou R, et al. Delayed hemolytic transfusion reaction in sickle cell disease patients: evidence of an emerging syndrome with suicidal red blood cell death. Transfusion. 2009;49(9): 1785-1792.
52. Sagiv E, Fasano RM, Luban NLC, et al. Glucose-6-phosphate-dehydrogenase deficient red blood cell units are associated with decreased posttransfusion red blood cell survival in children with sickle cell disease. Am J Hematol. 2018;93(5):630-634.
53. Gardner K, Hoppe C, Mijovic A, Thein SL. How we treat delayed haemolytic transfusion reactions in patients with sickle cell disease. Br J Haematol. 2015;170(6):745-756.
54. Mekontso Dessap A, Pirenne F, Razazi K, et al. A diagnostic nomogram for delayed hemolytic transfusion reaction in sickle cell disease. Am J Hematol. 2016;91(12):1181-1184.
55. de Montalembert M, Dumont M-D, Heilbronner C, et al. Delayed hemolytic transfusion reaction in children with sickle cell disease. Haematologica. 2011;96(6):801-807.
56. Win N, Sinha S, Lee E, Mills W. Treatment with intravenous immunoglobulin and steroids may correct severe anemia in hyperhemolytic transfusion reactions: case report and literature review. Transfus Med Rev. 2010;24(1): 64-67.
57. Dumas G, Habibi A, Onimus T, et al. Eculizumab salvage therapy for delayed hemolysis transfusion reaction in sickle cell disease patients. Blood. 2016;127(8):1062-1064.
58. Hayes C, Shafi H, Mason H, Klapper E. Successful reduction of plasma free-hemoglobin using therapeutic plasma exchange: a case report. Transfus Apheresis Sci. 2016;54(2):253-255.
59. Louie JE, Anderson CJ, Fomani KFM, et al. Case series supporting heme detoxification via therapeutic plasma exchange in acute multiorgan failure syndrome resistant to red blood cell exchange in sickle cell disease. Transfusion. 2018;58(2):470-479.
60. Schaer DJ, Buehler PW, Alayash AI, et al. Hemolysis and free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins. Blood. 2013;121(8):1276-1284.
61. Immenschuh S, Vijayan V, Janciauskiene S, Gueler F. Heme as a target for therapeutic interventions. Front Pharmacol. 2017;8:146.
62. Nance ST. Global definitions of rare donors. ISBT Sci Ser. 2013;8(1):23-27.
63. Gluckman E, Cappelli B, Bernaudin F, et al; Eurocord, the Pediatric Working Party of the European Society for Blood and Marrow Transplantation, and the Center for International Blood and Marrow Transplant Research. Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. Blood. 2017;129(11):1548-1556.
64. Allen ES, Srivastava K, Hsieh MM, et al. Immunohaematological complications in patients with sickle cell disease after haemo-poietic progenitor cell transplantation: a prospective, single-centre, observational study. Lancet Haematol. 2017;4(11): e553-e561.
65. Volt F. Red blood cell alloimmunisation in patients with sickle cell disease. Lancet Haematol. 2017;4(11):e506-e507.
66. Ribeil JA, Hacein-Bey-Abina S, Payen E, et al. Gene therapy in a patient with sickle cell disease. N Engl J Med. 2017;376(9):848-855.